title: Mutagenesis after therapy for Hodgkin's disease.
abstract: Therapy for Hodgkin's disease has been associated with a significant increase in risk for second cancers. To begin an investigation of the association of therapy-induced genetic damage with this risk, somatic mutations at the hypoxanthine phosphoribosyltransferase locus were measured in lymphocytes from patients previously treated for Hodgkin's disease. The results demonstrate that a subset of patients have persistently elevated mutation frequencies, perhaps suggesting that these individuals are among those at significant risk of second cancer development.
authors: Department of Cancer Biology, Harvard School of Public Health, Boston, Massachusetts.
authors: K T
authors: KT
authors: Kelsey
authors: M
authors: M
authors: Caggana-Aviles
authors: P
authors: P
authors: Mauch
authors: C N
authors: CN
authors: Coleman
authors: L N
authors: LN
authors: Shulman
authors: H L
authors: HL
authors: Liber
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D006689:Hodgkin Disease / Q000235:genetics / Q000628:therapy*; D006801:Humans; D008875:Middle Aged; D016296:Mutagenesis; D011446:Prospective Studies; D011878:Radiotherapy / Q000009:adverse effects